Evidence map›Paper›PMID 25592123›Full record

ArticleEye (London, England)2015

Prevalence and incidence of blindness and other degrees of sight impairment in patients treated for neovascular age-related macular degeneration in a well-defined region of the United Kingdom.

M Buckle, A Lee, Q Mohamed, E Fletcher, A Sallam, R Healy, I Stratton, A Tufail, R L Johnston

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Eye (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.6field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. Molecular and cellular imaging of the eye.Biomedical optics express · 2024
    Review
  2. Article
  3. Article
  4. Article
  5. Visual function quality of life measure changes upon conversion to neovascular age-related macular degeneration in second eyes.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2017
    Article
  6. Article
  7. Certification figures and their accuracy.Eye (London, England) · 2015
    Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

M BuckleDepartment of Ophthalmology, Gloucestershire Hospitals NHS Foundation Trust, Cheltenham Hospital, Cheltenham, UK.
A LeeMedical Retina Department, Moorfields Eye Hospital, London, UK.
Q MohamedDepartment of Ophthalmology, Gloucestershire Hospitals NHS Foundation Trust, Cheltenham Hospital, Cheltenham, UK.
E FletcherDepartment of Ophthalmology, Gloucestershire Hospitals NHS Foundation Trust, Cheltenham Hospital, Cheltenham, UK.
A SallamDepartment of Ophthalmology, Gloucestershire Hospitals NHS Foundation Trust, Cheltenham Hospital, Cheltenham, UK.
R HealyDepartment of Ophthalmology, Gloucestershire Hospitals NHS Foundation Trust, Cheltenham Hospital, Cheltenham, UK.
I StrattonGloucester Diabetic Retinopathy Research Group, Cheltenham General Hospital, Cheltenham, UK.
A TufailMedical Retina Department, Moorfields Eye Hospital, London, UK.
R L JohnstonDepartment of Ophthalmology, Gloucestershire Hospitals NHS Foundation Trust, Cheltenham Hospital, Cheltenham, UK.
Gloucestershire Hospitals NHS Foundation Trust · GBCheltenham General Hospital · GBMoorfields Eye Hospital · GBUniversity College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThis study aimed to evaluate the incidence and prevalence of blindness, sight impairment, and other visual acuity (VA) states in patients receiving ranibizumab for neovascular age-related macular degeneration (nAMD) in Gloucestershire.

methodsSerial VA and injection data for all treatment-naive patients receiving their first intravitreal injections of ranibizumab for nAMD in the Gloucestershire National Health Service Ophthalmology department between 2008 and 2010 were extracted from an electronic medical record system.

resultsThe prevalence of blindness (VA in the better-seeing eye ≤25 Early Treatment Diabetic Retinopathy Study (ETDRS) letters) at the time of first intravitreal injection was 0.8%, increasing to 3.5% after 3 years. The prevalence of sight impairment (VA in the better-seeing eye 26-39 ETDRS letters) increased from 4.1% at baseline to 5.5% after 3 years. The incidence of initiating ranibizumab treatment for nAMD in people aged ≥50 years in Gloucestershire was 111 people per 100 000 population in 2009, and 97 people in 2010. The incidence of patients meeting the visual criteria for blindness and sight impairment registration from treated nAMD in people aged ≥50 years in Gloucestershire was 3.5 and 9.7 people, respectively per 100 000 population in 2010.

conclusionThis is the first real-world study on the incidence and prevalence of eligibility for blindness and sight impairment registration in treated nAMD in the UK based on VA data. The incidence and prevalence of eligibility for certification of blindness or sight impairment in patients treated with ranibizumab for nAMD is low in Gloucestershire, with only 3.6% of the incident population progressing to blindness in 2010.

Indexed as

AgedAged, 80 and overAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedBlindnessFemaleHumansIncidenceIntravitreal InjectionsMaleMiddle AgedPersons with Visual DisabilitiesPrevalenceProspective StudiesRanibizumabRegistriesAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedRanibizumabVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID25592123
PMCPMC4366463
OpenAlexW1995437366

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.